EXAS vs LLY · rev $2.76B vs P/E 39, rev $22.97B
EXACT Sciences Corporation (EXAS) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
EXAS currently screens at market cap $20.03B. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the EXAS and LLY stock pages for the full models.
Not investment advice.